Moleculin Biotech Inc Stock News

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that recruiting has begun and

Is (MBRX) Outperforming Other Medical Stocks This Year?

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,

NEW YORK, May 27, 2020 -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading in Moleculin Biotech, Inc. (Nasdaq: MBRX) is scheduled to resume on Thursday, May 28,.

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,

Professor of Medicine at Yale and Director of The Yale New Haven Hospital Center for Outcomes Research and Evaluation Dr. Harlan Krumholz joins Yahoo Finance’s Seana Smith to discuss Moderna’s rec

NEW YORK, May 18, 2020 -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that the trading halt status in Moleculin Biotech Inc. (Nasdaq: MBRX) was changed to "additional.

Moleculin Biotech Inc. and CNS Pharmaceuticals Inc. said Monday their shares remain halted on Nasdaq with the exchange seeking additional information from each company. Shares werehalted temporarily

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,

Cell culture model: several compounds stop SARS-CoV-2 virus. A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells chang

The number of cases of COVID-19 rose above 4.1 million on Monday, as South Korea reported a new cluster stemming from Seoul’s nightclub district and China...

Moleculin Biotech Inc. and CNS Pharmaceuticals Inc. said Monday they did not solicit or have any advance knowledge about claims made by third parties about drug candidate WP1122 and its effect on CO

Moleculin Biotech Inc. undefined said Monday it did not solicit or have any advance knowledge about claims made by third parties about its drug candidate...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,

Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Moleculin Biotech, Inc. ("Moleculin" or the "Company") (NASDAQ: MBRX). Investors who purchased Molecul